Skip to content

KLRS KLRS Free cash flow

Discontinued — last reported Q4 '25

Free cash flow at other companies

Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Merck & Co. logo
Merck & Co.MRK
$2.93B+150%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-$81.55M-52.7%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$70.66M-51.6%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K

Valuation

See full
Market cap$96.83M+102%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Calculated from KLRS’s reported figures.

The official record: KLRS’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's free cash flow?
KLRS (KLRS) reported free cash flow of -$7.07M in Q4 2025.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.